Sunday 18 October 2026
Export PALI’s income statement to Excel — free account
Palisade Bio, Inc.
PALI Healthcare Biotechnology
Palisade Bio, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $250,000.00. In the quarter to June 2026, revenue grew 19,900.0%, EPS grew 91.4% and free cash flow fell 318.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
1.41
0.13
−8.44%
Follow PALI
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 3 | 1 | 4 | 6 | 5 |
P/E ratio |
— | — | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | (13.36) | — | — | (43.69) | (49.80) | (40.56) | (21.51) | (12.57) |
P/S ratio |
— | — | 15.41 | — | — | 1,085.33 | 144.64 | 10.73 | 70.27 | 2,238.89 |
Altman Z″-Score (non-manufacturers) |
— | — | (25.09) | — | — | (110.50) | (110.62) | (89.30) | (48.61) | (28.98) |
P/FCF ratio |
— | — | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | — | — | (7.05) | (0.66) | 10.17 | (2.88) |
P/Operating CF |
— | — | (1.44) | — | — | (9.47) | (1.09) | (1.68) | (7.99) | (8.89) |
P/B ratio |
— | — | 0.35 | — | — | 0.00 | 0.43 | 0.46 | 2.15 | 3.20 |
Price to Tangible BV |
— | — | 0.36 | — | — | 0.00 | 0.50 | 0.53 | 2.40 | 3.51 |
EV/Sales |
— | — | (31.89) | — | — | 1,117.04 | (175.75) | 8.00 | 44.89 | 1,378.22 |
EV/EBITDA |
— | — | 0.63 | — | — | 0.00 | 0.32 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | 0.74 | — | — | (3.16) | 0.37 | (0.27) | (0.87) | (1.43) |
EV/FCF |
— | — | 0.74 | — | — | (3.16) | 0.37 | (0.27) | (0.87) | (1.42) |
Quick Ratio |
28.77 | 3.03 | 4.81 | 4.11 | 4.20 | 0.10 | 4.19 | 5.85 | 7.95 | 2.76 |
Current Ratio |
28.95 | 3.24 | 5.15 | 4.89 | 4.61 | 0.11 | 4.61 | 6.19 | 8.22 | 2.85 |
Net Debt/EBITDA |
7.37 | 0.66 | 0.94 | 0.78 | 0.25 | (0.05) | 0.58 | 0.72 | 0.90 | 0.83 |
Debt/Assets |
0.29% | 0.73% | 1.12% | 0.56% | 0.70% | 37.79% | 2.75% | 0.00% | 0.00% | 16.39% |
Debt/Equity |
0.00 | 0.01 | 0.01 | 0.01 | 0.01 | (0.16) | 0.04 | 0.00 | 0.00 | 0.33 |
Asset Turnover |
0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.00 |
Operating CF/Net income |
0.65 | 0.84 | 0.90 | 0.94 | 0.56 | 0.46 | 0.87 | 1.56 | 0.86 | 0.74 |
Capex/Depreciation |
0.00 | 0.00 | (1.00) | (3.33) | 0.00 | (2.00) | 0.00 | (0.01) | (0.03) | (0.14) |
Interest Coverage |
(1,805.60) | (1,238.25) | (871.33) | (1,209.31) | (17.45) | (39.56) | (969.85) | (1,072.66) | (83.64) | (18.08) |
| (24.52%) | (153.59%) | (103.55%) | (143.75%) | 576.17% | 179.86% | (149.62%) | (67.72%) | (158.04%) | (258.77%) | |
| (23.11%) | (115.82%) | (82.62%) | (100.87%) | (342.75%) | (214.98%) | (117.07%) | (45.66%) | (85.87%) | (112.24%) | |
ROIC |
0.00% | 0.00% | 0.00% | (5,340.01%) | 0.00% | 0.00% | (2,809.80%) | (1,966.55%) | 0.00% | 0.00% |
Return on Tangible Assets |
(12.95%) | (198.84%) | (114.55%) | (121.56%) | (295.31%) | 143.74% | (187.13%) | (88.77%) | (141.04%) | (152.26%) |
Average Days of Receivables |
— | — | 0.00 | 0.00 | 0.00 | 1,595.19 | 500.10 | 502.58 | 521.67 | 1,432.96 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 2,757.20% | 0.00% | 0.00% | 22,955.56% | 26,373.38% | 1,523.15% | 3,113.88% | 81,209.26% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 2,480.80% | 0.00% | 0.00% | 45,911.11% | 29,776.62% | 1,753.58% | 2,104.23% | 46,279.01% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.10 | 0.06 | 0.04 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 249.60% | 0.00% | 0.00% | 14,918.52% | 5,719.48% | 243.88% | 680.77% | 21,268.52% |
Graham Net Nets |
— | — | 2.67 | — | — | (0.63) | 1.88 | 1.75 | 0.39 | 0.27 |
Graham Number |
— | — | 0.00 | — | — | 25,311.88 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | (311.91%) | — | — | (160.26%) | (382.05%) | (103.15%) | (63.01%) | (64.68%) |
Free Cash Flow Yield |
— | — | (280.98%) | — | — | (32.59%) | (326.32%) | (276.18%) | (73.50%) | (43.33%) |
Revenue per Share |
0.00 | 0.00 | 0.55 | 0.00 | 0.00 | 3.65 | 30.80 | 2,600.00 | 2,600.00 | 162.00 |
Operating CF per Share |
(0.19) | (8.61) | (24.41) | (227.60) | (1,191.37) | (1,288.65) | (14,511.40) | (76,924.00) | (134,162.00) | (156,161.00) |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.17) | 0.00 | (1.62) | 0.00 | (17.00) | (114.00) | (981.00) |
Free Cash Flow per Share |
(0.19) | (8.61) | (24.42) | (227.77) | (1,191.37) | (1,290.27) | (14,511.40) | (76,941.00) | (134,276.00) | (157,142.00) |
Cash per Share |
2.40 | 6.94 | 27.26 | 210.95 | 846.37 | 192.70 | 10,229.80 | 57,871.00 | 116,749.00 | 201,950.00 |
Shareholders Equity per Share |
2.32 | 5.29 | 24.81 | 212.59 | 593.95 | (1,918.65) | 10,252.00 | 60,496.00 | 85,151.00 | 113,308.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
Book value per Share |
2.32 | 5.29 | 24.81 | 212.59 | 593.95 | (1,918.65) | 10,252.00 | 60,496.00 | 85,151.00 | 113,308.00 |
Free Cash Flow |
(10.85) | (12.19) | (11.14) | (13.37) | (14.77) | (4.77) | (7.26) | (7.69) | (13.43) | (15.71) |
Working Capital |
129.59 | 7.26 | 10.74 | 11.72 | 9.01 | (7.19) | 4.42 | 5.46 | 10.93 | 13.57 |
Capital Expenditures |
— | — | 0.00 | (0.01) | — | (0.01) | — | 0.00 | (0.01) | (0.10) |
Net Current Asset Value |
129.26 | 7.11 | 10.59 | 11.45 | 6.36 | (9.22) | 4.19 | 4.87 | 7.08 | 9.63 |
EV/EBIT |
— | — | 0.63 | — | — | 0.00 | 0.31 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.02 | 0.00 | — | 0.44 | 0.00 | 0.01 | 0.04 | 6.06 |
Price to Operating Income |
— | — | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 1.00 | 0.40 | 0.30 | 0.67 | 0.60 | 3.51 | 2.06 | 2.02 | 2.54 |
Cash ROIC |
(4.12%) | (70.11%) | (46.59%) | (53.59%) | (82.31%) | 91.02% | (69.62%) | (65.00%) | (66.51%) | (44.60%) |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.34 | 0.08 | 0.71 | 1.19 | 0.32 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
Average Receivables |
— | — | — | 0.79 | 0.10 | 0.04 | 0.19 | 0.36 | 0.22 | 0.05 |
Average Payables |
0.94 | 0.90 | 1.23 | 1.54 | 1.93 | 1.68 | 0.83 | 0.85 | 1.61 | 1.90 |
Average Assets |
72.61 | 12.47 | 14.91 | 14.14 | 7.77 | 4.80 | 7.13 | 10.78 | 18.24 | 18.78 |
Average Common Equity |
68.43 | 9.40 | 11.89 | 9.92 | (4.62) | (5.74) | 5.58 | 7.27 | 9.91 | 8.14 |
Columns are period end dates